Conversely, it is reported in several cancer types that the majority of treatment‐expanded/post‐treatment exhausted T cells are derived from clonotypes present in pre‐treatment samples.[39, 95, 136] In a study by Magen A, et al.,[68] the proportion of TCRs shared between pre‐ and post‐treatment tumors was higher than that between post‐treatment tumors and either peripheral blood or LNs, suggesting a predominant local response.[85] The expansion of pre‐existing TCR clonotypes induced by PD‐1/PD‐L1 blockade is termed “clonal revival”[39] (Figure 3B, left panel). This evidence concerns the gene CD274 and cancer.